Publikationsliste Florian Lordick - Universitären Krebszentrum Leipzig

Publications list
Florian Lordick, M.D.
Original papers
1. Lordick F, Hauck RW, Senekowitsch R, Emslander HP. Atrial Natriuretic Peptide in Acute
Hypoxia-Exposed Healthy Subjects and in Hypoxaemic Patients. Eur Respir J 1995; 8: 216221
2. Lordick F, Gündel H, von Schilling C, Würschmidt F, Leps B, Sendler A, Schüßler J, Brandl
T, Peschel C und Sellschopp A. Structured Educational Group Interventions in Cancer
Patients: A Prospective Study to Evaluate its Implementation and Effectiveness at a German
University Hospital. Med Klin 2002; 97: 449-454
3. Lordick F, Hentrich M, Decker T, Hennig M, Pohlmann H, Hartenstein R, Peschel C.
Ultrasound Screening for Internal Jugular Vein Thrombosis Aids the Detection of Central
Venous Catheter-Related Infections in Patients with Haemato-Oncological Diseases: a
Prospective Observational Study. Brit J Haematol 2003; 120: 1073-1078
4. Lordick F, von Schilling C, Bernhard H, Hennig M, Bredenkamp R and Peschel C. Phase II
Trial of Irinotecan Plus Docetaxel in Cisplatin-Pretreated Relapsed or Refractory Oesophageal
Cancer. Br J Cancer 2003; 89: 630-633
5. Gundel H, Lordick F, Brandl T, Wurschmidt F, Schussler J, Leps B, Sendler A, Mert E,
Pouget-Schors D, von Schilling C, Peschel C, Sellschopp A. Interdisciplinary
Psychoeducational Intervention by Oncologists Proved Helpful for Cancer Patients. Z
Psychosom Med Psychother 2003; 49: 246-261
6. Ott K, Fink U, Becker K, Stahl A, Dittler HJ, Busch R, Stein H, Lordick F, Link T,
Schwaiger M, Siewert JR, Weber WA. Prediction of Response to Preoperative Chemotherapy
in Gastric Carcinoma by Metabolic Imaging: Results of a Prospective Trial. J Clin Oncol
2003; 21: 4604-4610
7. Wieder AH, Brücher BLDM, Zimmermann F, Becker K, Lordick F, Schwaiger M, Siewert
JR, Stein HJ, Fink U, Weber WA. Time Course of Tumor Metabolic Activity During
Radiochemotherapy of Esophageal Squamous Cell Carcinoma and Response to Treatment. J
Clin Oncol 2004; 22: 900-908
8. Ihbe-Heffinger A, Ehlken B, Bernard R, Berger K, Peschel C, Eichler HG, Deuson R,
Thödtmann J, Lordick F. The Impact of Delayed Chemotherapy-Induced Nausea and
Vomiting on Patients, Health Resource Utilization and Costs in German Cancer Centers. Ann
Oncol 2004; 15: 526-536
9. Voelter V, Schuhmacher C, Busch R, Peschel C, Siewert JR, Lordick F. Therapy-Related
Anemia in Patients Receiving Neoadjuvant Chemotherapy in Locally Advanced EsophagoGastric Cancer. Ann Thorac Surg 2004; 78: 1037-1041
10. Napieralski R, Ott K, Kremer M, Specht K, Vogelsang H, Becker K, Müller M, Lordick F,
Fink U, Siewert JR, Höfler H, Keller G. Combined GADD45A and thymidine phosphorylase
expression levels predict response and survival of neoadjuvant-treated gastric cancer patients.
Clin Cancer Res 2005; 15:3025-3031
11. Lorenzen S, Duyster J, Lersch C, von Delius S, Hennig M, Bredenkamp R, Peschel C and
Lordick F. Capecitabine plus docetaxel every three weeks in first- and second-line metastatic
oesophageal cancer: final results of a phase II trial. Brit J Cancer 2005; 92: 2129-2133
12. Lordick F, Lorenzen S, Stollfuss J, Vehling-Kaiser U, Kullmann F, Hentrich M, Zumschlinge
R, Dietzfelbinger H, Thoedtmann J, Hennig M, Seroneit T, Bredenkamp R, Duyster J, Peschel
C. Phase II Study of Weekly Infusional Fluorouracil, Folinic Acid, and Oxaliplatin (FUFOX)
in First Line Metastatic Gastric Cancer. Brit J Cancer 2005; 93: 190-194
13. Bubnoff N, Gorantla SHP, Kancha RK, Lordick F, Peschel C, Duyster J. The systemic
mastocytosis-specific activating cKIT mutation D186V can be inhibited by the kinase
inhibitor AMN107. Leukemia 2005; 19: 1670-1671
14. Wieder H, Beer A, Lordick F, Ott K, Fischer M, Rummeny EJ, Ziegler S, Siewert JR,
Schwaiger M, Weber WA. Comparison of Changes in Tumor Metabolic Activity and Tumor
Size During Chemotherapy of Adenocarcinomas of the Esophagus. J Nucl Med 2005; 46:
2029-2034
15. Hochster H, Kettner E, Kröning H, Becker K, Lordick F, Ramanathan RK, Macdonald J,
Hong S, John W, Schmoll HJ. Phase I/II Dose-Escalation Study of Pemetrexed plus Irinotecan
in Patients with Advanced Colorectal Cancer. Clin Colorectal Cancer 2005; 5: 257-262
16. Miething C, Feihl S, Mugler C, Grundler R, von Bubnoff N, Lordick F, Peschel C, Duyster
J. The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence
of imatinib. Leukemia 2006; 20: 650-657
17. Lordick F, Geinitz H, Theisen J, Sarbia M. Increased risk of ischemic bowel complications
during treatment with bevacizumab after pelvic irradiation: a report of three cases. Int J
Radiation Oncol Biol Physics 2006; 46: 1295-1298
18. Beer AJ, Wieder HA, Lordick F, Ott K, Fischer M, Becker K, Stollfuss J,Weber WA,
Rummeny EJ. Adenocarcinomas of the Esophagogastric Junction: MDCT for Evaluation of
Early Response to Neoadjuvant Chemotherapy. Radiology 2006; 239: 472-480
19. Bruecher BLDM, Becker K, Lordick F, Fink U, Sarbia M, Stein HJ, Busch R, Zimmermann
F, Molls M, Hoefler H, Siewert JR. The clinical impact of histopathological response
assessment by residual tumor cell quantification in esophageal squamous cell carcinomas.
Cancer 2006; 106: 2119-2127
20. Aapro M, Grunberg SM, Manikhas GM, Alexander FM, Suarez T, Tjulandin SA, Bertoli LF,
Yunus F, Morrica B, Lordick F, Macciochi A. A Phase III Double-Blind Randomized Trial of
Palonosetron Compared With Ondansetron in Preventing Chemotherapy-Induced Nausea and
Vomiting (CINV) Following Highly Emetogenic Chemotherapy. Ann Oncol 2006; 17: 14411449
21. Abbrederis K, Bassermann F, Schuhmacher C, Voelter V, Busch R, Rothling N, Sendler A,
Siewert JR, Peschel C, Lordick F. Erythropoietin-alfa for the management during
neoadjuvant chemotherapy for locally advanced oesophagogastric adenocarcinoma. Ann
Thorac Surg 2006; 82: 293-297.
22. Ott K, Vogelsang H, Marton N, Becker K, Lordick F, Kobl M, Schuhmacher C, Novotny A,
Mueller J, Fink U, Ulm K, Siewert JR, Hofler H, Keller G. The thymidylate synthase tandem
repeat promoter polymorphism: A predictor for tumor-related survival in neoadjuvant treated
locally advanced gastric cancer. Int J Cancer. 2006; 119: 2885-2894.
23. Ott K, Weber WA, Lordick F, Becker K, Busch R, Herrmann K, Wieder H, Fink U,
Schwaiger M, Siewert JR. Metabolic imaging predicts response, survival and recurrence in
adenocarcinomas of the esophagogastric junction (AEG) in a prospective trial. J Clin Oncol
2006; 24: 4692-4698
24. Witzig R, Schönberger B, Fink U, Busch R, Guendel H, Sendler A, Peschel C, Siewert JR,
Lordick F. Delays in diagnosis and therapy of gastric cancer and esophageal adenocarcinoma.
Endoscopy 2006; 38: 1122-1126
25. Lordick F, Ehlken B, Ihbe-Heffinger A, Berger K, Krobot KJ, Pellissier J, Davies G, Deuson
R. Health outcomes and cost-effectiveness of aprepitant in patients receiving antiemetic
prophylaxis for highly emetogenic chemotherapy in Germany. Eur J Cancer 2007; 42: 299307
26. Rodel C, Liersch T, Hermann RM, Arnold D, Reese T, Hipp M, Furst A, Schwella N, Bieker
M, Hellmich G, Ewald H, Haier J, Lordick F, Flentje M, Sulberg H, Hohenberger W, Sauer
R. Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. J Clin Oncol
2007; 25: 110-7
27. Wieder HA, Geinitz H, Rosenberg R, Lordick F, Becker K, Stahl A, Rummeny E, Siewert
JR, Schwaiger M, Stollfuss J. PET imaging with [(18)F]3'-deoxy-3'-fluorothymidine for
prediction of response to neoadjuvant treatment in patients with rectal cancer. Eur J Nucl Med
Mol Imaging 2007; 34: 878-883
28. Boeck S, Weigang-Kohler K, Fuchs M, Kettner E, Quietzsch D, Trojan J, Stotzer O, Zeuzem
S, Lordick F, Kohne CH, Kroning H, Steinmetz T, Depenbrock H, Heinemann V. Secondline chemotherapy with pemetrexed after gemcitabine failure in patients ith advanced
pancreatic cancer: a multicenter phase II trial. Ann Oncol 2007; 18: 745-51
29. Schuhmacher C, Lordick F, Bumm R, Tepe J, Siewert JR. Good advice is precious: the use
and value of “second opinion” given by an interdisciplinary cancer center: Dtsch Med
Wochenschr 2007; 132: 921-26
30. Wieder H, Rosenberg R, Lordick F, Geinitz H, Beer A, Becker K, Woertler K, Dobritz M,
Siewert JR, Rummeny EJ, Stollfuss JC. Rectal Cancer: MR imaging before neoadjuvant
chemotherapy and radiation therapy for prediction of tumor-free resections margins and longterm survival. Radiology 2007; 243; 744-51
31. Langer R, Specht K, Becker K, Ewald P, Ott K, Lordick F, Siewert JR, Hofler H.
Comparison of pretherapeutic and posttherapeutic expression levels of chemotherapyassociated genes in adenocarcinomas of the esophagus treated by 5-Fluorouracil- and
Cisplatin-based neoadjuvant chemotherapy. Am J Clin Pathol. 2007 128: 191-197
32. Lordick F, Ott K, Krause BJ, Weber WA, Becker K, Stein HJ, Lorenzen S, Schuster T,
Wieder H, Herrmann K, Bredenkamp R, Hoefler H, Fink U, Peschel C, Schwaiger M, Siewert
JR. Use of PET to assess early metabolic response and guide treatment of locally advanced
adenocarcinoma of the oesophagus and oesophagogastric junction: a feasibility study. Lancet
Oncology 2007; 8: 797-805
33. Napieralski R, Ott K, Kremer M, Becker K, Boulesteix AL, Lordick F, Siewert JR, Höfler H,
Keller G. Methylation of tumor related genes in neoadjuvant treated gastric cancer: relation to
therapy response, clinicopathological and molecular features. Clin Canc Res 2007; 13: 50955102
34. Siewert JR, Lordick F, Ott K, Stein HJ, Weber WA, Becker K, Peschel C, Fink U, Schwaiger
M. Induction chemotherapy in Barrett Cancer. Influence on Surgical Risk and Outcome. Ann
Surg 2007; 246: 624-631
35. Lorenzen S, Hentrich M, Haberl C, Heinemann V, Schuster T, Seroneit T, Roethling N,
Peschel C, Lordick F. Split-dose docetaxel, cisplatin, and leucovorin/5-fluorouracil as firstline therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction:
Results of a phase II trial. Ann Oncol 2007; 18: 1673-1679
36. Wieder HA, Ott K, Lordick F, Becker K, Stahl A, Herrmann K, Fink U, Siewert JR,
Schwaiger M, Weber WA. Prediction of Tumor Response by FDG-PET: Comparison of the
Accuracy of Single and Sequential Studies in Patients with Adenocarcinomas of the
Esophagogastric Junction. Eur J Nucl Med 2007; 34: 1925-1932
37. Herrmann K, Ott K, Buck AK, Lordick F, Wilhelm D, Souvatzoglu M, Becker K, Schuster
T, Wester HJ, Siewert JR, Schwaiger M, Krause BJ. Imaging gastric cancer with positron
emission tomography (PET) and the radiotracers 3'-deoxy-3'-[18F]fluorothymidine (FLT) and
FDG – a comparative analysis. J Nucl Med 2007; 48: 1945-1950
38. Lorenzen S, Herrmann K, Weber WA, Wieder H, Hennig M, Ott K, Bredenkamp R, Peschel
C, Schwaiger M, Lordick F. Visualisation of metastatic oesophageal and gastric cancer and
prediction of clinical response to palliative chemotherapy using (18)FDG PET.
Nuklearmedizin 2007; 46: 263-270.
39. Gündel H, Hümmeler V, Lordick F. Which tumor patients profit from interdisciplinary
psychoeducation in the framework of a tumor therapy? Z Psychosom Med Psychother 2007;
53: 324-38.
40. Rosenberg R, Nekarda H, Zimmermann F, Becker K, Lordick F, Hofler H, Molls M, Siewert
JR. Histopathological response after preoperative radiochemotherapy in rectal carcinoma is
associated with improved overall survival. J Surg Oncol 2008;97:8-13
41. Beer AJ, Lorenzen S, Metz S, Herrmann K, Watzlowik P, Wester HJ, Peschel C, Lordick F,
Schwaiger M. Comparison of Integrin {alpha}v{beta}3 Expression and Glucose Metabolism
in Primary and Metastatic Lesions in Cancer Patients: A PET Study Using 18F-Galacto-RGD
and 18F-FDG. J Nucl Med 2008; 49: 22-29
42. Rodel C, Arnold D, Hipp M, Liersch T, Dellas K, Iesalnieks I, Hermann RM, Lordick F,
Hinke A, Hohenberger W, Sauer R. Phase I-II Trial of Cetuximab, Capecitabine, Oxaliplatin,
and Radiotherapy as Preoperative Treatment in Rectal Cancer. Int J Radiat Oncol Biol Phys
2008: 70: 1081-1087
43. Boeck S, Hoehler T, Seipelt G, Mahlberg R, Wein A, Hochhaus A, Boeck HP, Schmid B,
Kettner E, Stauch M, Lordick F, Ko Y, Geissler M, Schoppmeyer K, Kojouharoff G, Golf A,
Neugebauer S, Heinemann V. Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus
gemcitabine(CapGem) versus gemcitabine plus oxaliplatin (GemOx): final results of a
multicenter randomized phase II trial in advanced pancreatic cancer. Ann Oncol 2008: 19:
340-47.
44. Abbrederis K, Lorenzen S, Fischer von Weikersthal L, Vehling-Kaiser U, Schuster T,
Roethling N, Peschel C, Lordick F. Weekly docetaxel
monotherapy for advanced gastric or esophagogastric junction cancer. Results of a phase II
study in pretreated patients or patients with impaired performance status. Crit Rev Oncol
Hematol 2008; 66: 84-90.
45. Ott K, Herrmann K, Lordick F, Wieder H, Weber WA, Becker K, Buck AK, Dobritz M, Fink
U, Ulm K, Schuster T, Schwaiger M, Siewert JR, Krause BJ. Early Metabolic Response
Evaluation by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography Allows In
vivo Testing of Chemosensitivity in Gastric Cancer: Long-term Results of a Prospective
Study. Clin Cancer Res. 2008;14:2012-2018.
46. Ott K, Lordick F, Becker K, Ulm K, Siewert J, Höfler H, Keller G. Glutathione-S-transferase
P1, T1 and M1 genetic polymorphisms in neoadjuvant-treated locally advanced gastric cancer:
GSTM1-present genotype is associated with better prognosis in completely resected patients.
Int J Colorectal Dis. 2008; 23: 773-782.
47. Bader F, Lordick F, Fink U, Becker K, Höfler H, Busch U, Siewert JR, Ott K. Paclitaxel in
the neoadjuvant treatment for adenocarcinomas of the distal esophagus (AEG I). A
comparison of two phase II trials with long term follow-up. Onkologie 2008; 31:366-372.
48. Arnold D, Höhler T, Dittrich C, Lordick F, Seufferlein T, Riemann J, Wöll E, Herrmann T,
Zubel A, Schmoll HJ. Cetuximab in combination with weekly 5-fluorouracil/folinic acid and
oxaliplatin(FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study
of the AIO GI Group. Ann Oncol. 2008; 19: 1142-1149
49. Lorenzen S, Brücher B, Zimmermann F, Geinitz H, Riera J, Schuster T, Roethling N, Höfler
H, Ott K, Peschel C, Siewert JR, Molls M, Lordick F. Neoadjuvant continuous infusion of
weekly 5-fluorouracil and escalating doses of oxaliplatin plus concurrent radiation in locally
advanced oesophageal squamous cell carcinoma: results of a phase I/II trial. Br J Cancer.
2008; 99: 1020-1026.
50. Schauer M, Stein H, Lordick F, Feith M, Theisen J, Siewert JR. Results of a Multimodal
Therapy in Patients with Stage IV Barrett's Adenocarcinoma. World J Surg. 2008; 32: 26552660.
51. Langer R, Ott K, Specht K, Becker K, Lordick F, Burian M, Herrmann K, Schrattenholz A,
Cahill MA, Schwaiger M, Höfler H, Wester HJ. Protein expression profiling in esophageal
adenocarcinoma patients reveals association of heat shock protein 27 expression and
chemotherapy response. Clin Cancer Res 2008, 14; 8279-8287.
52. Gross E, Busse B, Riemenschneider M, Neubauer S, Seck K, Klein HG, Kiechle M, Lordick
F, Meindl A. Strong association of a common dihydropyrimidine dehydrogenase gene
polymorphism with fluoropyrimidine-related toxicity in cancer patients. PLoS Medicine.
2008;3(12):e4003.
53. Rosenberg R, Herrmann K, Gertler R, Künzli B, Essler M, Lordick F, Becker K, Schuster T,
Geinitz H, Maak M, Schwaiger M, Siewert JR, Krause B. The predictive value of metabolic
response to preoperative radiochemotherapy in locally advanced rectal cancer measured by
PET/CT. Int J Colorectal Dis. 2009; 24: 191-200.
54. Abbrederis K, Lorenzen S, Rothling N, Ihbe-Heffinger A, Schuster T, Peschel C, Lordick F.
Chemotherapy-Induced Nausea and Vomiting in the Treatment of Gastrointestinal Tumors
and Secondary Prophylaxis with Aprepitant. Onkologie. 2009; 32: 30-34.
55. Ott K, Lordick F, Molls M, Bartels H, Biemer E, Siewert JR. Limited resection and free
jejunal graft interposition for squamous cell carcinoma of the cervical oesophagus. Br J Surg.
2009 Feb 17; 96: 258-266.
56. Ott K, Bader FG, Lordick F, Feith M, Bartels H, Siewert JR. Surgical Factors Influence the
Outcome After Ivor-Lewis Esophagectomy with Intrathoracic Anastomosis for
Adenocarcinoma of the Esophagogastric Junction: A Consecutive Series of 240 Patients at an
Experienced Center. Ann Surg Oncol. 2009; 16: 1017-1025.
57. Lorenzen S, Schuster T, Porschen R, Al-Batran SE, Hofheinz R, Thuss-Patience P, Moehler
M, Grabowski P, Arnold D, Greten T, Müller L, Röthling N, Peschel C, Langer R, Lordick F.
Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line
metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the
Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 2009; 20:1667-73.
58. Stocker G, Ott K, Henningsen N, Becker K, Hapfelmeier A, Lordick F, Hois S, Plaschke S,
Höfler H, Keller G. CyclinD1 and interleukin-1 receptor antagonist polymorphisms are
associated with prognosis in neoadjuvant-treated gastric carcinoma. Eur J Cancer
2009;45:3326-35.
59. Langer R, Ott K, Feith M, Lordick F, Siewert JR, Becker K. Prognostic significance of
histopathological tumor regression after neoadjuvant chemotherapy in esophageal
adenocarcinomas. Mod Pathol. 2009 Dec;22(12):1555-63.
60. Friederichs J, von Weyhern CW, Rosenberg R, Doll D, Busch R, Lordick F, Siewert JR,
Sarbia M. Immunohistochemical detection of receptor tyrosine kinases c-kit, EGF-R, and
PDGF-R in colorectal adenocarcinomas. Langenbecks Arch Surg. 2010;395(4):373-379
61. Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, Lang H,
Frilling A, Stoehlmacher J, Weitz J, Konopke R, Stroszczynski C, Liersch T, Ockert D,
Herrmann T, Goekkurt E, Parisi F, Köhne CH. Tumour response and secondary resectability
of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the
CELIM randomised phase 2 trial. Lancet Oncol. 2010; 11(1):38-47.
62. Lordick F, Luber B, Lorenzen S, Hegewisch-Becker S, Folprecht G, Wöll E, Decker T,
Endlicher E, Röthling N, Schuster T, Keller G, Fend F, Peschel C. Cetuximab plus
oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of
the Arbeitsgemeinschaft Internistische Onkologie (AIO). Br J Cancer 2010; 102(3):500-5.
63. Strumberg D, Schultheis B, Scheulen ME, Hilger RA, Krauss J, Marschner N, Lordick F,
Bach F, Reuter D, Edler L, Mross K. Safety, efficacy and pharmacokinetics of nimotuzumab,
a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients
with locally advanced or metastatic pancreatic cancer. Int J Clin Pharmacol Ther. 2010
Jul;48(7):473-5
64. Langer R, Ott K, Feith M, Lordick F, Specht K, Becker K, Hofler H. High pretherapeutic
thymidylate synthetase and MRP-1 protein levels are associated with nonresponse to
neoadjuvant chemotherapy in oesophageal adenocarcinoma patients. J Surg Oncol. 2010 Oct
1;102:503-8.
65. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A,
Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK; for the ToGA
Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy
alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer
(ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-97
66. Hofheinz RD, Al-Batran SE, Ridwelski K, Görg C, Wehle K, Birth M, Fetscher S, Scheiber
H, Lukan N, Lordick F. Population-based patterns of care in the first-line treatment of
patients with advanced esophagogastric adenocarcinoma in Germany. Onkologie.
2010;33(10):512-8
67. Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, André T, Chan E,
Lordick F, Punt CJ, Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E,
Tzekova V, Collins S, Oliner KS, Rong A, Gansert J. Randomized Phase III Study of
Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With
FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer. J
Clin Oncol 2010; 28(31):4706-13
68. Metz S, Ganter C, Lorenzen S, van Marwick S, Herrmann K, Lordick F, Nekolla SG,
Rummeny EJ, Wester HJ, Brix G, Schwaiger M, Beer AJ. Phenotyping of Tumor Biology in
Patients by Multimodality Multiparametric Imaging: Relationship of Microcirculation,
{alpha}v{beta}3 Expression, and Glucose Metabolism. J Nucl Med. 2010 Nov;51(11):1691-8.
69. Schuhmacher C, Gretschel S, Lordick F, Reichardt P, Hohenberger W, Eisenberger CF, Haag
C, Mauer ME, Hasan B, Welch J, Ott K, Hoelscher A, Schneider PM, Bechstein W, Wilke H,
Lutz MP, Nordlinger B, Van Cutsem E, Siewert JR, Schlag PM. Neoadjuvant Chemotherapy
Compared With Surgery Alone for Locally Advanced Cancer of the Stomach and Cardia:
European Organisation for Research and Treatment of Cancer Randomized Trial 40954. J Clin
Oncol 2010, 28: 5210-8
70. Lorenzen S, Panzram B, Keller G, Lordick F, Herrmann K, Becker K, Langer R, Schwaiger
M, Siewert JR, Ott K. Association of the VEGF 936C>T Polymorphism with FDG Uptake,
Clinical, Histopathological, and Metabolic Response in Patients with Adenocarcinomas of the
Esophagogastric Junction. Mol Imaging Biol 2011 Feb;13(1):178-86
71. Ströhlein MA, Lordick F, Rüttinger D, Grützner KU, Schemanski OC, Jäger M, Lindhofer H,
Hennig M, Jauch KW, Peschel C, Heiss MM. Immunotherapy of Peritoneal Carcinomatosis
with the Antibody Catumaxomab in Colon, Gastric, or Pancreatic Cancer: An Open-Label,
Multicenter, Phase I/II Trial. Onkologie. 2011; 34(3):101-8.
72. Moehler M, Mueller A, Trarbach T, Lordick F, Seufferlein T, Kubicka S, Geißler M,
Schwarz S, Galle PR, Kanzler S; German Arbeitsgemeinschaft Internistische Onkologie
(AIO). Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in
advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II
study. Ann Oncol. 2011; 22: 1358-1366
73. Moehler M, Mueller A, Hartmann JT, Ebert MP, Al-Batran SE, Reimer P, Weihrauch M,
Lordick F, Trarbach T, Biesterfeld S, Kabisch M, Wachtlin D, Galle PR; the German
Arbeitsgemeinschaft Internistische Onkologie (AIO). An open-label, multicentre biomarkeroriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric
cancer. Eur J Cancer. 2011; 47(10):1511-1520
74. Hübel K, Fresen MM, Salwender H, Basara N, Beier R, Theurich S, Christopeit M, Bogner C,
Galm O, Hartwig R, Heits F, Lordick F, Rösler W, Wehler D, Zander AR, Albert MH,
Dressler S, Ebinger M, Frickhofen N, Hertenstein B, Kiehl M, Liebler S, von Lilienfeld-Toal
M, Weidmann E, Weigelt C, Lange F, Kröger N. Plerixafor with and without chemotherapy in
poor mobilizers: results from the German compassionate use program. Bone Marrow
Transplant. 2011; 46: 2045-52
75. Ott K, Rachakonda PS, Panzram B, Keller G, Lordick F, Becker K, Langer R, Buechler M,
Hemminki K, Kumar R. DNA Repair Gene and MTHFR Gene Polymorphisms as Prognostic
Markers in Locally Advanced Adenocarcinoma of the Esophagus or Stomach Treated with
Cisplatin and 5-Fluorouracil-Based Neoadjuvant Chemotherapy. Ann Surg Oncol. 2011; 18:
2688-98.
76. Lorenzen S, von Gall C, Stange A, Haag GM, Weitz J, Haberkorn U, Lordick F, Weichert W,
Abel U, Debus J, Jager D, Munter MW. Sequential FDG-PET and Induction Chemotherapy in
Locally Advanced Adenocarcinoma of the Oesophago gastric Junction(AEG): The Heidelberg
Imaging Program in Cancer of the Oesophago-gastric junction during Neoadjuvant Treatment:
HICON Trial. BMC Cancer. 2011 Jun 24;11(1):266
77. Strumberg D, Schultheis B, Scheulen ME, Hilger RA, Krauss J, Marschner N, Lordick F,
Bach F, Reuter D, Edler L, Mross K. Phase II study of nimotuzumab, a humanized
monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally
advanced or metastatic pancreatic cancer. Invest New Drugs. 2012 Jun;30(3):1138-43
78. zum Büschenfelde CM, Herrmann K, Schuster T, Geinitz H, Langer R, Becker K, Ott K, Ebert
M, Zimmermann F, Friess H, Schwaiger M, Peschel C, Lordick F, Krause BJ. (18)F-FDG
PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the
esophagogastric junction: the MUNICON II trial. J Nucl Med. 2011 Aug;52(8):1189-96
79. Ott K, Herrmann K, Schuster T, Langer R, Becker K, Wieder HA, Wester HJ, Siewert JR,
Büschenfelde CM, Buck AK, Wilhelm D, Ebert MP, Peschel C, Schwaiger M, Lordick F,
Krause BJ. Molecular imaging of proliferation and glucose utilization: utility for monitoring
response and prognosis after neoadjuvant therapy in locally advanced gastric cancer. Ann Surg
Oncol. 2011 Nov;18(12):3316-23
80. Luber B, Deplazes J, Keller G, Walch A, Rauser S, Eichmann M, Langer R, Höfler H,
Hegewisch-Becker S, Folprecht G, Wöll E, Decker T, Endlicher E, Lorenzen S, Fend F,
Peschel C, Lordick F. Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from
a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). BMC Cancer. 2011
Dec 7;11:509.
81. Blank S, Bläker H, Schaible A, Lordick F, Grenacher L, Buechler M, Ott K. Impact of
pretherapeutic routine clinical staging for the individualization of treatment in gastric cancer
patients. Langenbecks Arch Surg. 2012 Jan;397(1):45-55
82. Berger AK, von Gall C, Abel U, Delorme S, Kloor M, Ose J, Weber TF, Stange A, Haag GM,
Haberkorn U, Lordick F, Jaeger D. A phase II study for metabolic in vivo response
monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonalantibody cetuximab in metastatic colorectal cancer: the Heidelberg REMOTUX trial. BMC
Cancer. 2012 Mar 22;12(1):108.
83. Rahbari NN, Lordick F, Fink C, Bork U, Stange A, Jager D, Luntz SP, Englert S, Rossion I,
Koch M, Buchler MW, Kieser M, Weitz J. Resection of the primary tumour versus no
resection prior to systemic therapy in patients with colon cancer and synchronous unresectable
metastases (UICC stage IV): SYNCHRONOUS - A randomized controlled multicentre trial
(ISRCTN30964555). BMC Cancer. 2012 Apr 5;12(1):142.
84. Lorenzen S, Blank S, Lordick F, Siewert JR, Ott K. Prediction of Response and Prognosis by
a Score Including Only Pretherapeutic Parameters in 410 Neoadjuvant Treated Gastric Cancer
Patients. Ann Surg Oncol. 2012; 19(7):2119-27
85. Warneke VS, Behrens HM, Böger C, Becker T, Lordick F, Ebert MP, Röcken C.
Her2/neu testing in gastric cancer: evaluating the risk of sampling errors. Ann Oncol.
2012 Nov 8. [Epub ahead of print]
86. Ott K, Blank S, Becker K, Langer R, Weichert W, Roth W, Sisic L, Stange A, Jäger
D, Büchler M, Siewert JR, Lordick F. Factors predicting prognosis and recurrence in
patients with esophago-gastric adenocarcinoma and histopathological response with
less than 10 % residual tumor. Langenbecks Arch Surg. 2012 Dec 27. [Epub ahead of
print]
Reviews and Editorials in peer-reviewed journals
1. Weber WA, Ott K, Lordick F. PET bei Ösophagus- und Magenkarzinom. Der
Nuklearmediziner 2003; 26: 104-109
2. Lordick F, Stein HJ, Peschel C, Siewert JR. Neoadjuvant therapy in oesophago-gastric
cancer. Br J Surg 2004; 91: 540-551
3. Stein HJ, Lordick F, Siewert JR. Ösophaguskarzinom. Chirurgische und multimodale
Therapie. Chirurgische Gastroenterologie 2004; 20:13-20
4. Stahl A, Wieder H, Wester HJ, Piert M, Lordick F, Ott K, Rummeny E, Schwaiger M, Weber
WA. PET/CT Molecular Imaging for Abdominal Oncology. Abdom Imaging 2004; 29: 388397
5. Lordick F, Rosenberg R, Stein HJ, Peschel C, Siewert JR. Adjuvant therapy for colon cancer.
Dtsch Med Wochenschr 2004; 129: 2366-2371
6. Rahden BHA, Lordick F. Adjuvante Chemotherapie beim Plattenepithelkarzinom des
Ösophagus. Chirurg 2004; 75: 637-638
7. Rahden BHA, Lordick F, Sendler A, Ulm K. Neuer Standard der adjuvanten Chemotherapie
beim Pankreaskarzinom. Chirurg 2004; 75: 1034-1036
8. Lordick F, Ihbe-Heffinger A, Peschel C. Antiemetic prophylaxis in the chemotherapy of
gastrointestinal tumours. Zeitschrift für Gastroenterologie 2005; 43: 391-398
9. Lordick F, Siewert JR. Multimodal treatment for gastric cancer. Gastric Cancer 2005; 8: 7885
10. Lordick F, Siewert JR. Neoadjuvant treatment for gastric cancer. Der Onkologe 2005; 11:
640-649
11. Lordick F, Peschel C, Siewert JR. Antibody-based targeted therapy for gastric cancer: is it
time to go for it? Gastric Cancer 2005; 8: 205-206
12. Lordick F. Neoadjuvant treatment for squamous cell cancer of the esophagus. Der Chirurg
2005; 76: 1025-1032
13. Braun-Falco M, Holtmann C, Lordick F, Ring J. Follicular drug reaction from cetuximab. A
common side effect in the treatment of metastatic colon carcinoma. Hautarzt 2006; 57: 701704
14. Siewert JR, Lordick F, Ott K, Brucher BL, Rosenberg R. Curative vs palliative strategies in
locoregional recurrence of gastrointestinal malignancies. Chirurg. 2006 239; 227-235
15. Reinacher-Schick A, Arnold D, Lordick F, Mohler M, Lutz MP, Seufferlein T. ASCO
Update 2006 - Highlights of the 42. Meeting of the American Society of Clinical
Oncology/ASCO 2006. Z Gastroenterol 2006; 44:1065-1072
16. Lordick F, Siewert JR. Perioperative chemotherapy versus surgery alone in resectable
gastroesophageal cancer. Chirurg 2006;77:1166-1167
17. Ebert M, Yu J, Lordick F, Röcken C. Proteomics in gastrointestinal cancer. Ann Oncol 2006;
17(Suppl10): 253-258
18. Siewert JR, Lordick F. Response prediction – early response evaluation. Consequences for
surgical oncology. Chirurg 2006:77:1095-1103
19. Bumm R, Feith M, Lordick F, Herrschbach P, Siewert JR. Impact of multidisciplinary tumor
boards on diagnosis and treatment of esophageal cancer. Eur Surg 2007; 39/3: 136-140
20. Lordick F, Ebert M, Stein HJ. Current treatment approach to locally advanced esophageal
cancer: Is resection mandatory? Future Oncology 2006;2:717-721
21. Lordick F, Ott K, Novotny A, Schuhmacher C, Siewert JR. R1 resection in the surgery of
upper gastrointestinal tumors. Relevance and therapeutical consequences. Chirurg 2007; 78:
792-801
22. Arnold D, Lordick F. Systemic treatment of peritoneal metastases. Chirurg 2007; 78: 1171122
23. Lordick F, Hölscher AH. Chirurgische und Internistische Diagnostik und Therapie des
Ösophaguskarzinoms. Gastroenterologie up2date 2007; 3: 291-319
24. Wieder H, Stahl A, Lordick F, Ott K. Esophageal Cancer. Recent Results Cancer Res 2008;
170: 71-79.
25. Van Cutsem E, Van de Velde C, Roth A, Lordick F, Köhne CH, Cascinu S, Aapro M. Expert
paper on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of
the European Organization for Research and Treatment of Cancer (EORTC) - Gastrointestinal
Cancer Group. Eur J Cancer 2008; 44: 182-194
26. Ott K, Lordick F, Herrmann K, Krause BJ, Schuhmacher C, Siewert JR. The new credo.
Induction chemotherapy in locally advanced gastric cancer. Consequences for surgical
stategies. Gastric Cancer 2008;11:1-9
27. Lordick F, Siewert JR. Bevacizumab (Avastin®) related surgical complications. Chirurg
2008; 79: 356-360
28. Lordick F, Schulze T. Molekulare Prognosefaktoren und neue systemische Therapien beim
Magenkarzinom. Der Onkologe 2008; ; 14: 389-395 DOI 10.1007/s00761-008-1339-8
29. Lordick F, Schulze T, Jäger D. The role of biologics in stomach cancer. Target Oncol
2008DOI 10.1007/s11523-008-0078-5.
30. Siewert JR, Lordick F, Ott K, Stein HJ. Adenocarcinoma of the distal esophagus (type 1) and
adenocarcinoma of the gastric cardia (type II): Is it one tumor entitiy? Ann Surg 2008; 247:
1081.
31. Heger U, Weitz J, Lordick F. Indications for pre- and postoperative treatment with imatinib
for GIST. Chirurg 2008; 79: 630-637.
32. Lordick F, Ruers T, Aust DE, Collette L, Downey RJ, El Hajjam M, Flamen P, Haustermans
K, Ilson D, Julié C, Krause BJ, Newiger N, Ott K, Roth A, Van Cutsem E, Weber WA, Lutz
M on behalf of the EORTC Gastrointestinal Cancer Tract Working Group. European
Organization of Research and Treatment of Cancer (EORTC) Gastrointestinal Tract Cancer
Working Group: workshop on the role of metabolic imaging in the neoadjuvant treatment of
gastrointestinal cancer. Eur J Canc 2008; 1807-1819.
33. Lordick F, Ott K, Weitz J, Jäger D. The evolving role for catumaxumab in gastric cancer.
Expert Opin Biol Ther 2008; 8: 1407-1415.
34. Lordick F, Krauß J, Jäger D. Tumor marker and biomarker in head and neck cancer. HNO,
Springer 2008: 56: 881-885.
35. Lordick F, Jäger D. The Current Status and Future of Biochemotherapy in Gastroesophageal
Cancers. Gastroint Canc Res 2008: 2: 187-197.
36. Ott K, Herrmann K, Krause BJ, Lordick F. The Value of PET Imaging in Patients with
Localized Gastroesophageal Cancer. Gastrointest Cancer Res. 2008 Nov;2(6):287-94.
37. Hartwig W, Strobel O, Lordick F, Büchler MW, Werner J. Multimodal therapy of esophageal
cancer. Z Gastroenterol. 2008 Oct;46(10):1207-13.
38. Lordick F, Ridwelski K, Al-Batran SE, Trarbach T, Schlag PM, Piso P. Treatment of Gastric
Cancer. Onkologie 2008; 31(suppl5):32-39
39. Lordick F. Multimodal treatment for adult soft tissue sarcomas. Chirurg 2009 80: 209-215.
40. Cmelak AJ, Lordick F, Borner M, Goldberg RM, Saif MW. Management of infusion
reactions in clinical trials and beyond: the US and EU perspectives. Oncology (Williston
Park). 2009; 23(2 Suppl 1): 18-25.
41. Lordick F, Ott K. Neoadjuvante und adjuvante Therapie des Magen- und
Ösophaguskarzinoms. Der Gastroenterologe 2009; 4: 224-231.
42. Ott K, Lordick F. Neoadjuvant therapy in the upper gastro-intestinal tract: Gastric cancer
from a surgical viewpoint. Chirurg 2009: 80: 1029-1034.
43. Lordick F. Principles of neoadjuvant therapy. Chirurg. 2009; 80: 1000-1005.
44. Czito B, Lordick F. Accomplishments in 2008 in the adjuvant treatment of rectal cancer.
Gastrointest Cancer Res. 2009 Sep;3(5 Supplement 2):S8-S14.
45. Lordick F, Lorenzen S. System therapy of esophageal carcinoma and the value of targeted
therapies. Onkologe 2010; 16: 515-520.
46. Lordick F, Grenacher L, Röcken C, Ebert M, Moehler M, Schumacher G. Diagnosis and
treatment of gastric cancer. Dtsch Med Wochenschr. 2010 Aug;135(34/35):1671-1682
47. Lordick F, Ott K, Krause BJ. New trends for staging and therapy for localized
gastroesophageal cancer: the role of PET. Ann Oncol. 2010 Oct;21 Suppl7:vii294-vii299.
48. Potthoff K, Hofheinz R, Hassel JC, Volkenandt M, Lordick F, Hartmann JT,Karthaus M,
Riess H, Lipp HP, Hauschild A, Trarbach T, Wollenberg A.Interdisciplinary management of
EGFR-inhibitor-induced skin reactions: a German expert opinion. Ann Oncol. 2011
Mar;22(3):524-35
49. Lordick F. Trastuzumab: a new treatment option for HER2-positive metastatic gastric and
gastroesophageal junction cancer. Future Oncol. 2011 Feb;7(2):187-99.
50. Moehler M, Al-Batran SE, Andus T, Anthuber M, Arends J, Arnold D, Aust D, Baier P,
Baretton G, Bernhardt J, Boeing H, Böhle E, Bokemeyer C, Bornschein J, Budach W,
Burmester E, Caca K, Diemer WA, Dietrich CF, Ebert M, Eickhoff A, Ell C, Fahlke J,
Feußner H, Fietkau R, Fischbach W, Fleig W, Flentje M, Gabbert HE, Galle PR, Geissler M,
Gockel I, Graeven U, Grenacher L, Groß S, Hartmann JT, Heike M, Heinemann V, Herbst B,
Herrmann T, Höcht S, Hofheinz RD, Höfler H, Höhler T, Hölscher AH, Horneber M, Hübner
J, Izbicki JR, Jakobs R, Jenssen C, Kanzler S, Keller M, Kiesslich R, Klautke G, Körber J,
Krause BJ, Kuhn C, Kullmann F, Lang H, Link H, Lordick F, Ludwig K, Lutz M, Mahlberg
R, Malfertheiner P, Merkel S, Messmann H, Meyer HJ, Mönig S, Piso P, Pistorius S, Porschen
R, Rabenstein T, Reichardt P, Ridwelski K, Röcken C, Roetzer I, Rohr P, Schepp W, Schlag
PM, Schmid RM, Schmidberger H, Schmiegel WH, Schmoll HJ, Schuch G, Schuhmacher C,
Schütte K, Schwenk W, Selgrad M, Sendler A, Seraphin J, Seufferlein T, Stahl M, Stein H,
Stoll C, Stuschke M, Tannapfel A, Tholen R, Thuss-Patience P, Treml K, Vanhoefer U, Vieth
M, Vogelsang H, Wagner D, Wedding U, Weimann A, Wilke H, Wittekind C. [German S3Guideline "Diagnosis and Treatment of Esophagogastric Cancer"]. Z Gastroenterol. 2011
Apr;49(4):461-531
51. Lordick F, Ott K, Krause BJ. Positron emission tomography - current role in the diagnosis
and treatment of upper gastrointestinal carcinomas. Dtsch Med Wochenschr. 2011
May;136(20):1061-1066
52. Lorenzen S, Lordick F. How will human epidermal growth factor receptor 2-neu data impact
clinical management of gastric cancer? Curr Opin Oncol. 2011; 23: 396-402
53. Van Cutsem E, Dicato M, Geva R, Arber N, Bang Y, Benson A, Cervantes A,Diaz-Rubio E,
Ducreux M, Glynne-Jones R, Grothey A, Haller D, Haustermans K, Kerr D, Nordlinger B,
Marshall J, Minsky BD, Kang YK, Labianca R, Lordick F, Ohtsu A, Pavlidis N, Roth A,
Rougier P, Schmoll HJ, Sobrero A, Tabernero J, Van de Velde C, Zalcberg J. The diagnosis
and management of gastric cancer: expert discussion and recommendations from the 12th
ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010. Ann Oncol. 2011 Jun;22
Suppl 5:v1-9
54. Ott K, Lordick F, Blank S, Büchler M. Gastric cancer: surgery in 2011. Langenbecks Arch
Surg. 2011; 6: 743-758
55. Lordick F. Current standard and trends in oesophageal cancer. Eur J Cancer. 2011 Sep;47
Suppl 3:S353-4
56. Lordick F, Ott K, Sendler A. [Gastric cancer and adenocarcinoma of the esophagogastric
junction : Principles of neoadjuvant therapy.]. Chirurg 2011 Nov;82(11):968-73.
57. Lordick F. HER2 in gastric cancer: a biomarker with clinical impact, but not without
translational challenges. Clin Transl Oncol. 2011 Sep;13(9):597-8
58. Meyer HJ, Hölscher AH, Lordick F, Messmann H, Mönig S, Schumacher C, Stahl M, Wilke
H, Möhler M. [Current S3 guidelines on surgical treatment of gastric carcinoma.]. Chirurg.
2012 Jan;83(1):31-7.
59. Lordick F. The role of PET in predicting response to chemotherapy in oesophago-gastric
cancer. Acta Gastroenterol Belg. 2011 Dec;74(4):530-5.
60. Lordick F. Supportive treatment – an integral part of cancer Care. Magazine of European
Medical Oncology 2012; 5: 1-2
61. Lordick F. Value of postoperative radiochemotherapy after completely resected gastric cancer
not definitive despite negative overall results of the ARTIST trial. Strahlenther Onkol. 2012
Jul;188(7):636-7.
62. Lordick F. Gastrointestinal cancer: Salvage chemotherapy in gastric cancer--more than a
straw? Nat Rev Clin Oncol. 2012 May 1;9(6):312-3.
63. Lordick F. To Resect or not resect in metastatic gastric cancer: that is the question. Gastric
Cancer 2012 Jul;15(3):229-31.
64. Lordick F. [Value of postoperative radiochemotherapy after completely resected gastric
cancer not definitive despite negative overall results of the ARTIST trial]. Strahlenther Onkol.
2012 Jul;188(7):636-7
65. Grenacher L, Schwarz M, Lordick F, Krause B, Roecken C, Moenig S, Ebert M, Jenssen C,
Kauczor HU, Moehler M. [S3 Guideline - Diagnosis and Treatment of Gastric Carcinoma:
Relevance for Radiologic Imaging.]. Rofo. 2012 Aug;184(8):706-12.
66. Lordick F, van Oorschot B. Palliative medicine in oncology. Objectives of the working group
on palliative medicine of the German Cancer Society. Forum 2012; 2012, DOI:
10.1007/s12312-012-0838-0 (online first)
67. Lutz MP, Zalcberg JR, Ducreux M, Ajani JA, Allum W, Aust D, Bang YJ, Cascinu S,
Hölscher A, Jankowski J, Jansen EP, Kisslich R, Lordick F, Mariette C, Moehler M, Oyama
T, Roth A, Rueschoff J, Ruhstaller T, Seruca R, Stahl M, Sterzing F, van Cutsem E, van der
Gaast A, van Lanschot J, Ychou M, Otto F. Highlights of the EORTC St. Gallen International
Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer
- Differential treatment strategies for subtypes of early gastroesophageal cancer. Eur J Cancer.
2012 Nov;48(16):2941-53
68. Lordick F. Optimizing neoadjuvant chemotherapy through the use of early response
evaluation by positron emission tomography. Recent Results Cancer Res 2012;196:201-11
69. Lordick F, Hölscher AH, Haustermans K, Wittekind C. Multimodal treatment of
esophageal cancer. Langenbecks Arch Surg. 2012 Sep 13. [Epub ahead of print]
Case reports in peer-reviewed journals
1. Apostolidis L, Kahlert C, Siegmund A, Thom R, Horstmann S, Jäger D, Lordick F.
Remission of Paraneoplastic Dermatomyositis Associated with Hepatocellular Carcinoma
under Prednisolone and Azathiopin, and Concommittant Sorafenib. Onkologie. 2009; 32:
50-53.
2. Berger AK, Bellos F, Siegmund A, Eisenbach C, Lordick F. Symptomatic hyponatraemia
caused by cylophosphamide. Onkologie. 2009; 32: 280-282.
Book Chapters and Book Editorship
1. Gündel H, Lordick F, Mert E, von Schilling C, Würschmidt F, Sellschopp A.
Psychoedukative Patientengruppen – Angloamerikanische Konzepte und ihre Umsetzung in
Deutschland. In: Empfehlungen zur Diagnostik, Therapie und Nachsorge Psychoonkologie.
Tumorzentrum München (Hrsg.). 1. Auflage 2002. W. Zuckschwerdt Verlag München, Bern,
Wien, New York.
2. Müller Ch, Strauss T, Zimmermann F, Lordick F, Schalhorn A. Pleuratumoren/malignes
Mesotheliom: Klinik, Diagnostik und Therapie. In: Manual des Tumorzentrums München. 6.
überarbeitete Auflage 2003. Zuckschwerdt Verlag München Wien New York.
3. Lordick F, Siewert JR. The Role of Induction Chemotherapy in Upper GI Cancer.
Proceedings of the 11th European United Gastroenterology Week 2003, Madrid, Spain.
4. Zimmermann F, Meining A, Lordick F, Sarbia M, Brücher B. ÖsophagusPlattenepithelkarzimom. In Manual des Tumorzentrums München, 7. Auflage 2006,
Zuckschwerdt Verlag München.
5. Sendler A, Prinz C, Janetschek P, Becker K, Grützner U, Lordick F, Schuhmacher C,
Zimmermann F. Magenkarzinom. In Manual des Tumorzentrums München, 7. Auflage 2006,
Zuckschwerdt Verlag München.
6. Peschel C, Lordick F (Hrsg.). Therapie-induzierte Nausea und Emesis in der Onkologie. 1.
Auflage 2006, Uni-Med Verlag Bremen, London, Boston.
7. Siewert JR, Stein HJ, Lordick F. Ösophaguskarzinom. In: Siewert JR, Rothmund M,
Schumpelick V (eds). Praxis der Viszeralchirurgie: Onkologische Chirurgie, 2. Auflage.
Berlin, Heidelberg, New York: Springer Verlag; Kapitel 35, S. 445-81
8. Siewert JR, Sendler A, Lordick F. Magenkarzinom. In: Siewert JR, Rothmund M,
Schumpelick V (eds). Praxis der Viszeralchirurgie: Onkologische Chirurgie, 2. Auflage 2006.
Berlin, Heidelberg, New York: Springer Verlag; Kapitel 35, S. 403-33
9. Siewert JR, Lordick F. Standards in der interdisziplinären Diagnostik und Therapie. In:
Kompendium Internistische Onkologie (Hrsg.: Schmoll, Höffken, Possinger), 4. Auflage
2006. Springer Verlag, Heidelberg, Berlin, New York.
10. Zimmermann F, Meining A, Lordick F, Sarbia M, Brücher BLDM (2006) ÖsophagusPlattenepithelkarzinom. In: Sendler A (ed). Manual Gastrointestinale Tumoren des
Tumorzentrum München. Empfehlungen zur Diagnostik, Therapie und Nachsorge. München:
Zuckschwerdt-Verlag; S. 1-18
11. Sendler A, Prinz C, Janetschek P, Becker K, Grützner U, Lordick F, Schuhmacher C,
Zimmermann F (2006) Magenkarzinom. In: Sendler A (ed). Manual Gastrointestinale
Tumorendes Tumorzentrum München. Empfehlungen zur Diagnostik, Therapie und
Nachsorge. München: Zuckschwerdt-Verlag; S. 26-53
12. Lordick F, Sendler A. Magenkarzinom. In: Diagnostik und Therapie gastrointestinaler
Tumoren (Hrsg. Illiger und Schmoll). Uni-Med Verlag AG Bremen – London – Boston; in
press
13. Nieder C, Lordick F. Combination of platinum compounds and ionizing radiation: In: Brown
JM, Mehta MP, Nieder C. Multimodal Concepts for Integration of Cytotoxic Drugs and
Radiation Therapy. Springer Berlin, Heidelberg, New York 2006, 1. Auflage.
14. Siewert JR, Molls M, Zimmermann F, Lordick F. Esophageal Cancer – Clinical
Management. In: Kelsen DP, Daly JM, Kern SE, Levin B, Tepper JE. Gastrointestinal
Oncology. Principles and Practice. Lippincott Williams & Wilkins, Philadelphia 2007; 2nd
edition.
15. Sendler A, Lordick F, Tannapfel A. Das Magenkarzinom. In: Hiddemann W (Hsg.)
Onkologie, Springer Berlin, Heidelberg, New York, 2007; 2. Auflage.
16. Lordick F. Therapiestrategien bei Patienten mit synchron metastasierten kolorektalen
Karzinomen. In Bokemeyer (Hrsg.): Das kolorektale Karzinom – Grundlagen, Prävention und
moderne Therapiekonzepte. SocioMed Verlag 2007; 1. Auflage.
17. Lordick F, Sendler A. Magenkarzinom. In: Therapiekonzepte bei gastrointestinalen Tumoren.
Hrsg. Schmoll & Arnold, Uni-Med Verlag, Bremen, 2009. 1. Auflage.
18. Siewert JR (Herausgeber), Lordick F (Redaktion). Praxis der Viszeralchirurgie –
Onkologische Chirurgie. Springer Verlag Heidelberg Berlin New York 2010, 3. Auflage.
ISBN 978-3-642-03807-5
19. Lordick F. Biologisch zielgerichtete Therapie. In Siewert JR, Lordick F: Praxis der
Viszeralchirurgie – Onkologische Chirurgie. Springer Verlag Heidelberg Berlin New York,
2010, 3. Auflage. ISBN 978-3-642-03807-5
20. Lordick F, Beiglböck A, Jäger D, Siewert JR. Multidisziplinarität im Cancer Center. In
Siewert JR, Lordick F: Praxis der Viszeralchirurgie – Onkologische Chirurgie. Springer
Verlag Heidelberg Berlin New York, 2010, 3. Auflage. ISBN 978-3-642-03807-5
21. Lordick F, Hölscher AH. Esophageal Cancer. In: Blanke, Roedel, Talamonti: Gastrointestinal
Oncology, a Practical Guide. Springer Heidelberg Berlin New York, 2010, 1. Edition, ISBN
Nummer 978-3-642-13305-3
22. Lordick F (Herausgeber): Biologie und zielgerichtete Therapie des Magenkarzinoms. 1.
Auflage 2011; Uni-Med Verlag AG Bremen – London – Boston
23. Lordick F, Peschel V (Herausgeber): Therapie-induzierte Nausea und Emesis in der
Onkologie. 3. Auflage 2011; Uni-Med Verlag AG Bremen – London – Boston
Selected Invited Lectures in 2005
Multimodal Treatment in Esophageal and Gastric Cancer
Clinical Grand Round Lecture, University of Lausanne
Lausanne, 12th January 2005
Gastric Cancer – Options Beyond Chemotherapy
Congress of the Arbeitsgemeinschaft Internistische Onkologie
Würzburg, 16 March 2005
Adjuvant Therapy in Colon Cancer
Congress of the German Surgical Society
Munich, 6th April 2005
Impact of Chemotherapy-Induced Nausea and Vomiting on Quality of Life and Health
Care Utilization
Congress of the Multinational Society of Supportive care in Cancer
Geneva, 30 June 2005
MultimodalTreatment Strategies in Gastrointestinal Stroma Tumors
International Surgical Week, Durban
South Africa, 22nd August 2005
Adenocarcinoma of the Esophago-Gastric Junction. Neoadjuavnt Treatment
Strategies in Locally Advanced Tumors
International Surgical Week
Durban, South Africa, 22nd August 2005
Multimodal Concepts in Esophageal Cancer
60. Annual Meeting of the German Society of Gastroenterology
Cologne, 16th September 2005
EGF-Receptor Inhibition in the Treatment of SolidTumors
University Clinic Frankfurt and Tumorzentrum Frankfurt/Main
Frankfurt, 21st September 2005
Multimodal Treatment for Locally Advanced Cancer of the Oesophagus and Stomach
Annual Meeting of the German Society of Hematology and Medical Oncology
Hannover, 2nd October 2005
Molecular Targeted Therapy
22nd Annual Meeting of the Austrian Society of Surgical Oncology
St. Wolfgang; 6th October 2005
Modern Antibody Therapy, New Chances – New Toxicities
Symposium of the Projektgruppe “Gastrointestinale Tumoren” Munich, 26 th October
2005
FDG-PET guided chemotherapy
Biological Imaging for Therapy Selection and Tumor Response Monitoring; Munich,
3rd December 2005
Selected Invited Lectures in 2006
Treatment Standards in Colorectal Cancer
University of Marburg-Giessen
Giessen, 12th January 2006
The Impact of “Response” During Neoadjuvant Therapy – Clinical Consequences
German Cancer Congress
Berlin, 25th March 2006
Esophageal and Gastric Cancer: Multimodal Treatment Strategies
German Cancer Congress
Berlin, 26th March 2006
Current Development in the Treatment of Gastric Cancer
2. Hamburger Onkologie Forum, University Hospital Eppendorf, Hamburg
Hamburg, 22th April 2006
Current Concepts in the Treatment of Gastrointestinal Tumors – Therapy of Gastric
Cancer
112th Congress of the German Society for Internal Medicine
Wiesbaden, 26th April 2006
Should locally advanced esophageal cancer be resected?
8th World Congress on Gastrointestinal Cancer
Barcelona, 29th June 2006
Neoadjuvant therapy in esophageal cancer: What is evidence-based?
10th Interdisciplinary Nürnberg Symposium
Nürnberg, 15th July 2006
Early evaluation of response in the treatment of solid tumors by PET
Munich Cancer Research Congress
Munich, 20th July 2006
Response-guided treatment algorithms: neoadjuvant therapy of locally advanced
adenocarcinoma of the esophagogastric junction (AEG) as a model (late-breaking
abstract oral session)
Annual Meeting of the European Society of Medical Oncology
Istanbul, 2nd October 2006
Adverse event reporting: Consequences for conception of clinical studies and the
interpretation of study data
4th Good Clinical Practice (GCP) course. Klinikum rechts der Isar, TU Munich
Munich, 4th October 2006
Perioperative therapy of cardia and gastric cancer
Annual Meeting of the German Society of Hematology and Medical Oncology
Leipzig, 8th November 2006
Selected Invited Lectures in 2007
Update in Gastroeneterology: Esophageal and Gastric Cancer
1st Munich Gastroenterology Symposium
Munich, Germany 3rd February 2007
Update in the Oncological Treatment of Esophageal and Gastric Cancer
13. AGO Winter Course (Arbeitsgemeinschaft für Gastroenterologische Onkologie)
Salzburg, Austria 9th February 2007
Treatment of Stage II Colon Cancer
EORTC Update Course in Gastrointestinal Oncology
Berlin, 3 March 2007
Treatment of Locally Advanced and Metastatic Gastric Cancer
EORTC Update Course in Gastrointestinal Oncology
Berlin, Germany 3 March 2007
Neoadjuvant Therapy Concepts in Gastric Cancer
9th Postgraduate Course in Surgical Oncology.
Biel, Switzerland, 10 May 2007
Translational Oncology Update in Colorectal Cancer
International Symposium on Translational Oncology
Barcelona, Spain, 18 May 2007
Early response prediction with PET/CT
World Congress of Gastrointestinal Cancer
Barcelona, Spain, 28 June 2007
Standard Treatment of Metastatic Gastric and Esophageal Cancer
Gastrointestinal Cancer Oncology Update 2007
Wiesbaden, Germany, 30 June 2007
Perioperative Chemotherapy in Potentially Resectable and Locally Advanced
Irresectable Gastric Cancer: a New Standard?
11th Multidisciplinary Nuernberg Symposium
Nuernberg, Germany, 6 July 2007
Surgical versus Non-Surgical Approaches to Treat Squamous Cell Carcinoma of the
Esophagus
42nd World Congress of the International Society of Surgery
Montréal, 27 August 2007
Perioperative Treatment in Cancers of the Gastroesophageal Junction
42nd World Congress of the International Society of Surgery
Montréal, 28 August 2007
Preoperative-/induction therapy: Early Response Prediction in GI Tract Cancer: An
Unmet Need
1st International Essen Conference on Multimodal Treatment of Cancer
Essen, 21 September 2007
Esophageal Cancer. Is resection always necessary?
Standars in Diagnosis and Treatment of Esophageal Cancer. University of Bonn
Bonn, 26 September 2007
Meet the Expert Seminar: Neoadjuvant and Systemic Treatment in Gastric Cancer.
Annual Congress of the German, Austrian and Swiss Societies for
Hematology/Oncology (G/A/SSHO)
Basel, 6 October 2007
Imaging for Early Response Assessment
Annual Symposium of the Gastrointestinal Cancer Working Group of the EORTC
Mainz, 10 November 2007,
Early assessment of response to chemotherapy in gastrointestinal cancers.
Symposium for the treatment of gastrointestinal tumors at the University of Bologna
Bologna, 29 November 2007
Combining platinum compounds in gastrointestinal (non-colorectal) cancer
X Meeting of the International Society for Platinum Coordination Compounds
Verona 2 December 2007
Selected Invited Lectures 2008
How to predict response to neoadjuvant chemotherapy in gastro-esophageal cancer
5th Meeting of the Belgian Digestive Oncology Society
Brussels, 12 January 2008
First-line systemic chemotherapy in metastatic colorectal cancer
State-of-the-art meeting of the North German hematologists/medical oncologists
Hannover, 19 January 2008
Individualized perioperative treatment planning in gastro-esophageal cancer
28th German Cancer Congress
Berlin, 20 February 2008
Chair of the 3rd Annual Course on GI Cancer; an ESMO labelled course
29 February – 1 March 2008, Munich
Progress in Gastric Cancer Therapy: EORTC guidelines
3rd Annual Course on GI Cancer; an ESMO labelled course
29 February 2008, Munich
Clinical trials in Thoracic Tumors: The European Perspective
21st Ginsberg Meeting of the American Toracic Surgery Society
13 March 2008, San Diego, CA
Response-guided Treatment of Esophageal Cancer
21st Ginsberg Meeting of the American Toracic Surgery Society
13 March 2008, San Diego, CA
Assessment of Response to Preoperative Treatment
EORTC-GI Scientific symposium
“Management of gastro-oesophageal junction cancer”
5 April 2008, Strasbourg, France
Multimodal Treatment of Gastric Cancer
Gastro-intestinal Tumor Sympsoium at the University of Regensburg
23 April 2008, Regensburg, Germany
Chemotherapy in Esophago-gastric Cancer
1st Heidelberg Gastric and Esophageal Cancer Meeting
9 May 2009, Heidelberg, Germany
Novel Approaches in the Treatment of gastric and Esophageal Cancer
British Columbia Cancer Agency
27 May 2008, Vancouver, BC, Canada
Standards in Multimodal Treatment of Esophago-Gastric Cancer
University of British Columbia, Vancouver General Hospital
29 May 2008, Vancouver, BC, Canada
EORTC lecture: How to integrate PET/CT into the treatment management of
gastrointestinal cancer.
10th World Congress of GI Cancer
28 June 2008, Barcelona, Spain
Molecular predictive markers in the treatment of colorectal cancer.
UICC World Cancer Congress
30 August 2008, Geneva, Switzerland
Standards and Perspectives in the treatment of tumors at the gastroesophageal
junction
University of Rouen
20 September 2008, Rouen, France
Response-Prediction to neoadjuvant Radiochemotherapy by PET in gastric and
esophageal cancer. Session Chair.
2nd Annual Meeting of the German Societies of Gastroenterology and Visceral
Surgery
2 October 2008, Berlin
Indications for the adjuvant and neoadjuvant treatment of gastric cancer
2nd Annual Meeting of the German Societies of Gastroenterology and Visceral
Surgery
3 October 2008, Berlin
Gastric and Esophageal Cancer – Trimodal Therapy?
Chair of an Educational Session at the Annual Meeting of the German, Austrian and
Swiss Societies of hematology and Medical Oncology.
11 October 2008, Vienna
Oesophageal Cancer – Oncological Therapy
23rd Annual Meeting of the Gastroenterologische Arbeitsgemeinschaft RheinlandPfalz/Saarland
24 October 2008, Bad Kreuznach
Current Trends in the Treatment of Gastric Cancer
Scientific Grand Round at the Medizinische Hochschule Hannover
11 November 2008, Hannover
Selected Invited Lectures 2009
PET Scan in Oesophageal and Gastric Cancer. What is its Clinical Objective Value?
International Surgical Meeting
22 January 2009, Lissabon, Portugal
Chair of the EORTC/ESMO Teaching Course GI Oncology
27-28 February 2009, Nice, France
Current Treatment of Gastric Cancer
EORTC/ESMO Teaching Course
27-28 February 2009, Nice, France
Novel Approaches in the Multimodal Treatment of Esophageal Cancer
Spring Symposium of The German Society of Hematology/Oncology (DGHO)
13 March 2009; Berlin, Germany
PET-Imaging as a Biomarker for the Multimodal Treatment of Esophageal Cancer
Spring Meeting of the EORTC
20 March 2009, Brussels, Belgium
Behandlung des Ösophaguskarzinoms
Trainings- und zertifizierungskurs der Deutschen Gesellschaft für Verdauungs- und
Stoffwechselkranheiten (DGVS)
27 March 2009, Berlin, Germany
PET/CT in the Staging and Therapy Monitoring of Esophageal Cancer
Meeting of the Royal Society of Medicine, Section of Radiology
31 March 2009, London, United Kingdom
Intraperitoneale Therapie bei malignem Aszites
Tagung der Rhein-Main-Arbeitsgemeinschaft für Gastroenterologie
1 April 2009, Frankfurt
Aktuelle systemische Therapie des Magenkarzinoms
GI Oncology Update 2009 der Fachgesellschaften
3. Juli 2009, Wiesbaden
Aktuelle Therapie des Magenkarzinoms
Symposium der Universität Halle
22. August 2009, Halle
Innovative Ansätze zur multimodalen Therapie bei Adenokarzinomen des gastroösophagealen Übergangs
Medizinische Hochschule Hannover
26. August 2009, Hannover
Session Chair: Selected abstracs non-colorectal GI cancers: oral presentations.
Congress of the European Society of Medical Oncology (ESMO),
23 September 2009, Berlin
Session Chair Education Session: New directions in the treatment of gastric cancer.
Congress of the European Society of Medical Oncology (ESMO),
24 September 2009, Berlin
Vorsitz Fortbildungssymposium: Therapieupdate Ösophagus-, Magen-, Pankreasund Leber-Karzinom
Kongress der Deutschen Gesellschaft für Hämatologie und Onkologie
4. Oktober 2009, Mannheim
Innovative Therapie bei Tumoren des gastro-ösophagealen Übergangs
Kongress der Deutschen Gesellschaft für Hämatologie und Onkologie
4. Oktober 2009, Mannheim
Integration of Molecular Imaging into Clinical Management of Esophageal Cancer
Swedish Medical Society Trial Meeting
9 October 2009, Stockholm, Sweden
Molecular Imaging in the Clinical Management of Gastric and Esophageal Cancer
EORTC GI group Autumn Symposium
10 October 2009, Ghent, Belgium
Imaging Biomarkers During Systemic Therapy of Cancer
European Association of Nuclear Medicine Congress
14 October 2009, Barcelona, Spain
Imaging Biomarkers during Chemotherapy of Upper GI Cancers
EORTC-NCI-ASCO Translational Research Symposium
17 October 2009, Brussels, Belgium
Neoadjuvante Chemo- und Radiochemotherapiekonzepte – Was ist wirklich
gesichert?
Onkologisches Fokusseminar Siloah: Therapie des Ösophaguskarzinoms
23. Oktober 2009, Hannover
Prävention und multimodale Therapie des Ösophaguskarzinoms
Falk-Symposium, Universität Magdeburg
5. Dezember 2009, Magdeburg
Selected Invited Lectures 2010
Behandlung solider Tumorerkrankungen – Vorsitz
Kongress der Niedergelassenen Onkologen Niedersachsens
23. Januar 2010, Hannover
Update Onkologie des oberen Verdauungstrakts und GIST
Update Onkologie 2010
30. Januar 2010, Berlin
Her2-neu und EGFR bei Magenkarzinom
Deutscher Krebskongress 2010
24.2.2010, Berlin
Neoadjuvante Therapiekonzepte beim Magenkarzinom - Evidenzlage aus
randomisierten Phase III Studien
Deutscher Krebskongress 2010
25.2.2010, Berlin
Nuklearmedizinische Bildgebung - Einfluss auf onkologische Behandlungsstrategien.
Therapiesteuerung mit PET
Deutscher Krebskongress 2010
25.2.2010, Berlin
Kontroversen in der Behandlung von gastrointestinalen Tumoren. Neoadjuvante
Therapie des Barrettkarzinoms
Deutscher Krebskongress 2010
25.2.2010, Berlin
Neoadjuvant Chemotherapy or Chemoradiotherapy for Esophagogastric Cancer
5th EORTC Wintercourse 2010
5.-6.3.2010, Frankfurt
Biologisch zielgerichtete Therapie des Magenkarzinoms
Westdeutsches Tumorzentrum und Universitätsklinik Essen
12.4.2010, Essen
Biologisch zielgerichtete Therapie des Magenkarzinoms
1. Magenkarzinom-Symposium der Universität Kiel
11. Juni 2010 Kiel
Should all patients with localized gastric cancer receive adjuvant/neoadjuvant
therapy?
12th World Congress of Gastrointestinal Cancer
1 July 2010 Barcelona
Standards in der systemischen Therapie des Magenkarzinoms
GI Oncology 2010 – 6. Interdisziplinäres Update
3. Juli 2010, Wiesbaden
Update Adenokarzinom des Ösophagus – Neoadjuvante Therapie und
Responseevaluation
65. Jahrestagung der Deutschen Gesellschaft für Verdauungs- und
Stoffwechselkrankheiten
16. September 2010, Stuttgart
Kliniker und Pathologe im Gespräch: Pathologie nach neoadjuvanter Therapie und
Regressionsgrading – Ösophagus und Magen
65. Jahrestagung der Deutschen Gesellschaft für Verdauungs- und
Stoffwechselkrankheiten
18. September 2010, Stuttgart
Meet the Expert Seminar: Therapie des Magenkarzinoms.
Jahrestagung der Deutschen und Schweizer Gesellschaft für Hämatologie/Onkologie
2. Oktober 2010, Berlin
New trends for staging and therapy for localized gastroesophageal cancer: the role of
PET.
35th Annual Meeting of the European School of Medical Oncology (ESMO)
10th October 2010, Milan, Italy
Selected Invited Lectures 2011
PET-guided treatment in locally advanced adenocarcinoma of the esophagogastric
junction (AEG): the MUNICON II study (best abstract oral presentation)
2011 ASCO Gastrointestinal Cancer Symposium
20 January 2011, San Francisco, CA, USA.
Response Prediction in Upper GI Cancer: Update of the MUNICON Study.
13th Belgian Week of Gastroenterology
18th February 2011, Liège, Belgium
Malignes Lymphom: Klinische Perspektive
Jahrestagung der Norddeutschen Röntgengesellschaft
19. Februar 2011, Braunschweig
PET CT in a neoadjuvant setting – from a clinical oncologist’s standpoint
14th Annual PET/CT Meeting of the Royal Society of Medicine
14 March 2011, London, UK
Diagnostik und perioperative Therapie des Magenkarzinoms
Symposium „Im Onkologischen Fokus – Magenkarzinom“ Otto-von-Guericke-
Universität Magdeburg
2. April 2011, Magdeburg
Leiter des Workshops „Young Medical Oncologists”
Arbeitsgemeinschaft Internistische Onkologie
9.-10. April 2011, Berlin
Onkologische Perspektive Magenkarzinom
Fortbildungsreihe „Interdisziplinäre Viszeralmedizin“
Universitätsklinikum Halle
13. April 2011, Halle
Ösophaguskarzinom und Magenkarzinom
Seminar Onkologische Gastroenterologie der Deutschen Gesellschaft für
Verdauungs- und Stoffwechselkrankheiten (DGVS)
15.-16. April 2011, Berlin
Ösophaguskarzinom – kurative Therapie
117. Kongress der Deutschen Gesellschaft für Innere Medizin
30. April 2011, Wiesbaden
Discussion Lecture: Gastrointestinal Cancers (non-colorectal) Oral abstracts
presentation session
2011 American Society of Clinical Oncology Annual Meeting
7 June 2011, Chicago
Targeted Therapy in Gastric Cancer
13th World Congress on Gastrointestinal Cancer
23 June 2011, Barcelona, Spain
Molecular Imaging for Response Monitoring in Esophageal Cancer
36th European Multidisciplinary Cancer Congress of the ESMO-ECCO
24th September 2011, Stockholm, Sweden
Current Standards and New Trends in Esophageal Cancer
36th European Multidisciplinary Cancer Congress of the ESMO-ECCO
25th September 2011, Stockholm, Sweden
Treatment of Gastric Cancer and EGJ Tumors: State of the Art
8th Annual Symposium of the Aarbeitsgemeinschaft Internistische Onkologie (AIO)
19 November 2011, Berlin, Germany
Treatment of Metastatic Gastric Cancer: HER2 and other Novel Targets
Invited Lecture at McGill University
30 November 2011, Montréal, Canada
Treatment of Localized Gastric Cancer
Invited Lecture at Université de Montréal
1st December 2011, Montréal, Canada
Treatment of Esophago-Gastric Cancer: Current Standards
Invited Lecture at Laval University
2nd December 2011, Québec, Canada
Selected Invited Lectures 2012
New Trends in the medical and neoadjuvant treatment of esophageal cancer
Invited lecture at the Clinic of Surgery, University of Heidelberg
15 February 2012, Heidelberg, Germany
Treatment of metastatic esophageal cancer
30th German Cancer Congress
22 February 2012, Berlin, Germany
Esophageal cancer: chemotherapy, radiotherapy and new trends
114th Congress of the German Society of Internal Medicine
14 April 2012
Molecular diagnostic and targeted therapy in gastric cancer
Invited lecture at the University of Kiel
28 April 2012, Kiel, Germany
Impact of adjuvant chemotherapy in gastric cancer
Third European Gastric Cancer International Workshop
8 June 2012, Cologne, Germany
Standard chemotherapy in advanced gastric cancer
World Congress of Gastrointestinal Cancer
28 June 2012, Barcelona, Spain
Perioperative and palliative therapy of esophageal cancer
8th Interdisciplinary GI Oncology Update
7 July 2012, Wiesbaden, Germany
Esophageal and gastric cancer – new directions in neoadjuvant treatment
Annual Meeting of the German Society of Gastroenterology (DGVS)
20 September 2012, Hamburg, Germany
Oncological strategies for the treatment of colorectal and non-colorectal liver
metastases
Annual Meeting of the German Society of Hematology and Oncology
20 October 2012, Stuttgart, Germany
Patient selection for GI cancer treatment, Plenary Lecture
Annual Meeting of the Hungarian Society of Cancer
10 November 2012, Budapest, Germany
Role of PET-CT in Staging and Monitoring of Esophageal Cancer
United European Gastroenterology Federation, UEGW
24 October 2012, Amsterdam
Gastroesophageal Junction Adenocarcinoma: Can Early Response Evaluation
Change the Neoadjuvant Treatment?
European Organization of Research and Treatment of Cancer
1 December 2012, Lisbon
Neo- and Adjuvant Treatment for Gastric Cancer
ESMO Preceptorship Program
7 December 2012, Berlin, Germany
Biologically Targeted Treatment for Gastric Cancer
ESMO Preceptorship Program
8 December 2012, Berlin, Germany
Leipzig, 10 January 2013
Prof. Dr. Florian Lordick